News for Blueprint Medicines Stock (BPMC)

Currently The Schall Law Firm Is Investigating Possible Violations Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/27/24

At Present The Schall Law Firm Is Probing Potential Securities Law Violations For Stock Owners Of Blueprint Medicines Corporation

Accesswire • 06/26/24

The Schall Law Firm Is At Present Investigating Possible Breaches Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/25/24

The Schall Law Firm Is Currently Probing Potential Securities Law Violations For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/24/24

At The Moment The Schall Law Firm Is Probing Potential Securities Law Violations For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/23/24

At Present The Schall Law Firm Is Probing Potential Securities Law Violations For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/21/24

The Schall Law Firm Is At Present Probing Potential Securities Law Violations For Investors Of Blueprint Medicines Corporation

Accesswire • 06/19/24

Currently The Schall Law Firm Is Investigating Possible Securities Law Breaches For Blueprint Medicines Corporation Investors

Accesswire • 06/18/24

At Present The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Advantage Of Blueprint Medicines Corporation (NASDAQ:BPMC) Investors

Accesswire • 06/18/24

Currently, Investigations Into Potential Violations Of Securities Laws For The Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC) Are Being Conducted By The Schall Law Firm

Accesswire • 06/12/24

Currently, The Schall Law Firm Is Undertaking Probes Into Possible Breaches Of Securities Laws For The Benefit Of Blueprint Medicines Corporation (NASDAQ:BPMC) Investors

Accesswire • 06/11/24

Currently, The Schall Law Firm is Actively Probing Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)

Accesswire • 06/09/24

Presently, The Schall Law Firm is Conducting Investigations into Potential Securities Law Violations for the Advantage of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)

Accesswire • 06/08/24

Currently, The Schall Law Firm is Undertaking Probes into Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)

Accesswire • 06/07/24

At Present, The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Accesswire • 06/06/24

Currently, The Schall Law Firm Is Probing Allegations For Possible Securities Laws Breaches On Behalf Of Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC)

Accesswire • 06/05/24

The Schall Law Firm is Currently Investigating Claims on Behalf of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC) for Potential Violations of Securities Laws

Accesswire • 06/04/24

BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Accesswire • 06/03/24

IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Accesswire • 06/02/24

IMPORTANT ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Accesswire • 06/01/24

IMPORTANT ACTION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Accesswire • 05/31/24

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

PRNewsWire • 05/30/24

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Accesswire • 05/30/24

Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

PRNewsWire • 05/23/24

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire • 05/06/24